[
  {
    "variant_id": {
      "Gene": "EGFR",
      "Protein_Change": {
        "ref": "L",
        "alt": "R",
        "position": "858"
      },
      "variant_string_id": "EGFR L858R"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper describes that EGFR mutations, including L858R, lead to constitutive activation of the kinase domain, resulting in uncontrolled cell growth and oncogenesis in non-small cell lung cancer.",
        "judgment": "Yes",
        "reasoning": "The disease mechanism is clearly defined as involving EGFR's role in signal transduction and how mutations like L858R disrupt normal regulation."
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The paper uses a cell viability assay to assess the effect of EGFR inhibitors on cells harboring the L858R mutation.",
        "judgment": "Yes",
        "reasoning": "Cell viability assays are widely accepted for evaluating the effectiveness of targeted therapies in cancer, directly modeling the disease mechanism."
      },
      {
        "step_name": "Step 3a: Basic Controls and Replicates",
        "extracted_paper_info": "The paper includes both wild-type EGFR as a negative control and known activating mutations (e.g., Del746-753) as positive controls. The experiments were performed in triplicate, with data from three independent experiments.",
        "judgment": "Yes",
        "reasoning": "Both normal/negative and abnormal/positive controls are used, and multiple replicates are included."
      },
      {
        "step_name": "Step 3c: Variant Controls",
        "extracted_paper_info": "The paper does not explicitly mention using known pathogenic or benign variants as direct controls for the L858R mutation in this assay.",
        "judgment": "No",
        "reasoning": "While basic controls are present, variant-specific controls (e.g., other P/LP or B/LB variants) are not described."
      },
      {
        "step_name": "Step 4b: No OddsPath Calculation",
        "extracted_paper_info": "The paper does not provide statistical analyses or mention OddsPath for the L858R mutation. However, it states that at least 10 benign/pathogenic variant controls were used across the study.",
        "judgment": "Yes",
        "reasoning": "While sufficient benign/pathogenic controls are used, no OddsPath calculation is provided."
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_supporting"
    },
    "overall_conclusion": "The functional evidence for EGFR L858R supports its classification as pathogenic. While basic controls and replicates are present, the lack of variant-specific controls and statistical analysis limits the strength of the evidence to supporting level."
  }
]